drugset / Trial / NCT01436643
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) antidepressants over 16 weeks as add-on to fingolimod treatment. It is designed to evaluate the safety and tolerability of this combination in this patient population based on an immunomodulatory treatment with fingolimod.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citalopram | Small molecule | 40 mg | — |
| Subject | Fluoxetine | Small molecule | 40 mg | — |
| Subject | Venlafaxine | Small molecule | 150 mg | — |
| Background | Fingolimod | Small molecule | 0.5 mg | Oral |